About Encellin
Encellin is a Healthcare company based in San Francisco (United States) founded in 2015 by Crystal Nyitray. Developer of regenerative materials. Encellin has raised $18.45 million across 4 funding rounds from investors including Khosla Ventures, Y Combinator and SV Latam Capital. Its chief executive, as recorded, is Crystal Nyitray. Encellin offers products and services including ENCRT. Its focus areas include Life Sciences, Wound Care, Medical Devices and Therapeutic Devices. Its competitors include Organogenesis, Sofregen and BioTissue; 3 of its 3 listed competitors have raised funding.
Company details
Encellin is developing regenerative materials using cell transplant therapy. The company has developed cell transplant therapy for treating missing, damaged, or diseased cells and treatment of chronic diseases.
- Headquarters San Francisco, United States
- Founders Crystal Nyitray
- SectorsHealthcare
- Website encellin.com
- Social LinkedIn X
- Total Equity Funding$18.45M (USD)
in 4 rounds
- Latest Funding Round$9.94M (USD), Series A
Sep 2023
- InvestorsKhosla Ventures
& 3 more
Products & Services of Encellin
Encellin offers a comprehensive portfolio of products and services, including ENCRT.
Implant that encapsulates cells to deliver therapeutics for chronic diseases.
Funding Insights of Encellin
Encellin has successfully raised a total of $18.45M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $9.94 million completed in September 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $18.45M
- Total Rounds 4
- Last Round Series A — $9.94M
- First Round $2.11M
(Jul 2019)
- Investors Count 4
All 4 funding rounds of Encellin with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2023 | $9.94M | Series A | – | Khosla Ventures | |
| Aug 2021 | $5.9M | Seed | – | Khosla Ventures, SV Latam Capital | |
| Aug 2019 | $500,000 | Seed | – | Y Combinator | – |
| Jul 2019 | $2.11M | Seed | – | – | – |
4 investors in total: 4 institutional.
Investors in Encellin
Encellin has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Khosla Ventures, Y Combinator and SV Latam Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage startups are funded by this venture capital firm. | 2004 | khoslaventures.com | Menlo Park, United States | |
Early-stage startups are accelerated via funding and educational programs. | ycombinator.com | Mountain View, United States | ||
Venture capital firm investing in science and technology startups | svlatamcap.com | San Francisco, United States | ||
Angel funding is provided to Silicon Valley-based companies. | sandhillangels.com | Mountain View, United States |
Investor details for Encellin
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Encellin
9 people are tracked at Encellin (4 in leadership, 5 in board & advisors).
| Name | Role | Group |
|---|---|---|
Crystal Nyitray | Founder & CEO | Leadership |
Steve Boyd | CTO | Leadership |
Grace Wei | COO & Co-Founder | Leadership |
광문 백 | Director | Leadership |
Mike German | Diabetes Advisor | Board & advisors |
Becky Foster | Advisor | Board & advisors |
Vern Norviel | Advisor | Board & advisors |
Tejal Desai | Technology Expert & Founder | Board & advisors |
Greg Szot | Preclinical Advisor | Board & advisors |
Complete people profiles for Encellin
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Encellin
3 dated milestones of Encellin across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Encellin is founded.
- Funding First funding round of $2.1M.
- Funding Latest funding round, Series A, of $9.9M.
Competitors of Encellin
Encellin has 3 listed competitors in our database, 3 of them funded. They include Organogenesis, Sofregen and BioTissue.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| organogenesis.com | 1985 | Canton, United States | $30M | 856 | Regenerative therapies for wound care are developed and commercialized. | |
| sofregen.com | 2014 | Medford, United States | $17.8M | 8 | Silk-derived biomaterials are developed for soft tissue repair in surgery. | |
| biotissue.com | 2001 | Miami, United States | $110.04M | 234 | Regenerative biologic therapies for eye care are developed and provided. |
Detailed competitors of Encellin
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Wound Care
3 companies that operate in the same segment as Encellin (Wound Care) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanotech-based wound care products are developed and provided. | 2010 | Madison, Wisconsin, United States | USD 22.7 M | 35 | ||
Regenerative biomaterial products and bioimplants for wound, surgical, sports medicine and orthopedics | 1985 | Marietta, Georgia, United States | USD 418.63 M | 837 | ||
Developer of hemostatic products for wound care | 2010 | New York, New York, United States | USD 113.35 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Encellin
Complete news archive for Encellin
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Encellin
Encellin was founded in 2015 and raised its 1st funding round 4 years after it was founded.
Encellin is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Crystal Nyitray is the CEO of Encellin, as recorded in our data. They have also founded this company.
Encellin is a funded company, having raised a total of $18.45M across 4 funding rounds to date. The company's 1st funding round was a Seed of $2.11M, raised on Jul 2019.
Encellin is developing regenerative materials using cell transplant therapy. The company has developed cell transplant therapy for treating missing, damaged, or diseased cells and treatment of chronic diseases.
Encellin's top competitors include Organogenesis, Sofregen and BioTissue.
Encellin offers ENCRT.
Encellin has 4 investors. Key investors include Khosla Ventures, Y Combinator, SV Latam Capital, and Sand Hill Angels.